Physicians’ Opinions Survey on FDA’s Bydureon Approval

Published : Mar-2012

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions


Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample

Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents


Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market

Report methodology
Datamonitor consulting


List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

G1 Therapeutics Inc (GTHX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary G1 Therapeutics Inc (G1 Therapeutics), formerly G Zero Therapeutics Inc is a healthcare company that develops novel, and small molecule therapies. The company pipeline products include CDK4/6, trilaciclib G1T28 a drug candidate; G1T38 a potential best compound, and G1T48. It undertakes discovery and development of innovative small molecules for utilization in cancer therapy and biodefense applications. G1 Therapeutics discovers new small molecule-based methods that prevent the hematological side effects of cancer chemotherapy and exposure to ionizing radiation. The company also develops small molecules to target specific proteins associated with cell proliferation and growth. It operates through its laboratory located Research Triangle Park. G1 Therapeutics is headquartered in R......

Humabs BioMed SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Humabs BioMed SA (Humabs) is an antibody therapeutics biotechnology company that discovers and develops human monoclonal antibodies. The company's pipeline programs include Flu A virus, ebola virus, HBV, rabies virus, JCV, dengue, and others. It develops cellclone technologies, a proprietary platform that delivers a pipeline of human monoclonal antibodies, and demonstrates the antibodies effectiveness in both in-vivo and in-vitro. Humabs technology platform uses immortalized B cells or cultured plasma cells obtained from the blood or lymphoid organs of the donor. The company's pipeline products are used in the treatment of cancer, inflammatory and infectious diseases. It partners with pharmaceutical companies, government agencies, academic institution, and universities. Humabs i......

Nanolek – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Nanolek specializes in the production of import-substituting and novel pharmaceuticals. The company's product portfolio includes vaccines; drugs for treatment of leukemias, brain cancer, breast cancer, stomach and ovarian cancer, colorectal cancer, HIV infection and other diseases. Nanolek also conducts clinical trials on generic, biosimilar and innovative products. It develops drugs in solid dosage forms, and cytostatic drugs in solid and injectable dosage forms through its production facility. Nanolek also offers contract manufacturing services to various organizations such as Merck, Aspen and Aspen Holdings. The company is a joint venture between Rusnano Corp and Epidbiomed. Nanolek is headquartered in Moscow, Russia. Nanolek - Pharmaceuticals & Healthcare - Deals and Alli......

PRA Health Sciences Inc (PRAH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary PRA Health Sciences Inc (PRA) is a contract research organization(CRO) which provides clinical development services. The company offers services such as phase I-IV study management, and embedded and functional outsourcing services. It offers solutions in bioanalytical laboratories, biometrics, clinical pharmacology, strategic solutions, post-marketing research, clinical diagnostics, and safety and risk management. PRA spans its expertise in the therapeutic areas of biosimilars, oncology, hematology, respiratory, rare diseases, neurology, infectious diseases, cardio-metabolic and immunology. It caters to pharmaceutical and biotechnology industries. The company has presence in the US, Hong Kong, Russia, India, France, Italy, China, Japan, South Africa, Israel and Colombia among ot......

National Taiwan University Hospital – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary National Taiwan University Hospital (NTUH) is a healthcare service provider that offers biomedical, clinical research and patient care services. The hospital's research activities include community-based intervention programs, multicenter controlled clinical trials, program projects, research and development projects, and research training programs. It provides diagnosis and treatment of cancer, hepatitis, and organ transplantation. NTUH develops diagnosis and treatment in the areas of immunology, dermatology, ophthalmology, cardiovascular, infertility, orthopedics and microsurgery. The hospital offers cellular and molecular studies related to normal structure and function. It also promotes international cooperation in order to gain experience and knowledge from the medical deve......

Mednax Inc (MD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Mednax Inc (Mednax) is a national medical group company, which operates a network of physician service providers. The company offers a wide range of neonatal, anesthesia, maternal-fetal, pediatric physician and subspecialty services. Its network includes other pediatric subspecialists comprising physicians providing pediatric intensive care; pediatric cardiology care, hospital-based pediatric care and pediatric surgical care. Mednax also provides other services related to healthcare facilities and physicians, through complementary businesses, consisting of a revenue cycle management company and a consulting services company. The company through its affiliated professional corporations has presence in several states across the US and in Puerto Rico. Mednax is headquartered in Sun......

Libbs Farmaceutica Ltda – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Libbs Farmaceutica Ltda (Libbs Farmaceutica) is a pharmaceutical company which offers biological drug products. The company offers monoclonal antibodies in various specialties which include cardiovascular, gynecology, oncology, dermatology, respiratory, and central nervous system transplant. It also offers active pharmaceutical ingredients, drugs and other medical products. Libbs Farmaceutica provides products in several dosage forms including injectable solutions, drops, tablets, capsules, coated tablets, powders, moisturizing fluids, gels and creams. The company carries its synthesis of active ingredients and manufacturing of medicines at its units located in Barra Funda and Embu das Artes, Sao Paulo. Libbs Farmaceutica is headquartered in Sao Paulo, Brazil. Libbs Farmaceut......

PharmaCell BV – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary PharmaCell BV (PharmaCell) is a contract manufacturing organization that offers services for cellular therapies and regenerative medicine. The organization manufactures commercial cell therapy products in the European markets. Its services include cell culture scale-up, manufacturing of advanced therapeutic medicinal products, process development, transfer of technologies and controlled temperature transportation. PharmaCell provides capacity reservation and patient treatment scheduling and shipper validation, among others. The organization offers its services in the areas of operations, technology transfer, process development and logistics. It manufactures clinical trial material in Phase I to Phase III clinical trials. PharmaCell is headquartered in Maastricht, the Netherland......

Newcastle University – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Newcastle University (NU) is an educational university that offers teaching and research services. The university provides teaching and study services including postgraduate study, undergraduate study, and campus services. It offers teaching services in areas of accounting and finance; agri-business management, agriculture, ancient history, animal science, archaeology, biology and zoology. NU also provides services in business management, chemical engineering, civil engineering, classics and ancient history; computing science, history, journalism, law and others. The university offers research programs in humanities and social sciences; medical sciences, science, agriculture and engineering areas. It also provides accommodation to its students. The university has its operations ......

Endo Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Endo Pharmaceuticals Inc (Endo Pharmaceuticals), a subsidiary of Endo International plc is a healthcare products provider that offers medicinal products. The company manufactures and distributes generic pharmaceutical products and over-the-counter medications. Its products include testosterone undecanoate injection CIII, buprenorphine buccal film CIII, alprostadil for injection, testosterone gel CIII, frovatriptan succinate tablets, lidocaine patch, cyanocobalamin, and others. Endo Pharmaceuticals provides USP nasal spray, testosterone nasal gel Clll, oxymorphone hydrochloride injection CII, and oxymorphone hydrochloride tablets CII, among others. It offers its products for the treatment of various therapeutic areas such as pain management, men's health, urology, orthopedics and......